Welcome to our dedicated page for EUDA Health Holdings news (Ticker: EUDA), a resource for investors and traders seeking the latest updates and insights on EUDA Health Holdings stock.
EUDA Health Holdings Limited reports developments across non-invasive and preventive healthcare in Asia, with a focus on Singapore, Malaysia and China. Company updates include longevity and personalized healthcare services, regenerative medicine access, stem cell extraction and cryogenic storage, and commercial arrangements for selected cellular immunotherapies, including TCR-T-related therapies supplied through Shenzhen Inno Immune.
EUDA announcements also cover public-company capital actions and Nasdaq listing matters. Recent corporate developments include ordinary-share adjustments, warrant amendments and cancellations, registered share offerings, and governance actions tied to its capital structure as a Nasdaq-listed foreign private issuer.
EUDA Health (NASDAQ: EUDA) will launch EUDA Helixé 2.0 in January 2026 as an upgraded premium vitality and longevity supplement.
Key changes include a 20% increase in New Zealand deer placenta powder (from 100 mg to 120 mg), replacement of L-glutathione with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent), advanced preservation and delivery methods (freeze drying, refining, nitrogen encapsulation, and nano emulsification replacing enteric coating), a new proprietary bottle design, and New Zealand Halal certification to enable broader Muslim-market distribution.
EUDA (NASDAQ: EUDA) launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen on Dec 23, 2025, accelerating its regenerative-medicine strategy.
The company is upgrading Shenzhen Inno’s cGMP facility into a production and innovation center integrating GO POSB’s iPSC platform and technologies from two Japanese partners to support iPSC expansion, stem cell preparation and T-cell immunotherapies. EUDA also holds distribution rights for Shenzhen Inno’s T-cell immunotherapies and stated an intention to acquire GO POSB. The Shenzhen clinic will offer advanced cell therapies, AI-guided life-cycle management, and integrated Eastern/Western/functional medicine.
EUDA Health Holdings (NASDAQ: EUDA) announced on December 22, 2025 a technology integration that adds the QB utility token into its digital health and rewards platform.
Customers and agents can earn and redeem QB tokens for EUDA offerings including Bioenergy Capsule treatments, Euda Helixe supplements, and selected stem cell services. EUDA will receive QB tokens solely in exchange for products and services, recorded as non-monetary, product-based transactions.
The QB token is built on Binance Smart Chain and interoperates with the USD1 stablecoin (1:1 redeemable for US dollar) using Chainlink CCIP; QB Limited is the token issuer and exclusive distributor of Euda Helixe in Hong Kong and Macau.
EUDA Health Holdings (NASDAQ: EUDA) announced plans to integrate a third‑party utility cryptocurrency called QB into its digital health and rewards platform, with QB scheduled for launch in January 2026. The token will be usable across EUDA’s ecosystem for payments, rewards, and access to healthcare products and partner services in Singapore, Malaysia, and China. EUDA also plans to hold QB in its digital asset treasury to support long‑term financial flexibility and participation in blockchain initiatives. The initiative aims to link healthcare engagement with decentralized finance to enhance loyalty, access, and community participation.
EUDA Health Holdings (NASDAQ: EUDA) announced it entered a securities purchase agreement dated November 26, 2025 to sell a convertible warrant to Streeterville Capital for an aggregate purchase price of US$100,000. The Warrant is exercisable into up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share and was offered under the company’s Form F-3 shelf registration (File No. 333-282723) with a related prospectus supplement.
The Warrant allows cash-only exercise for 90 days from issuance (subject to extension). The company may require partial forced exercise up to 10% of cumulative dollar trading volume if the share price is ≥ US$7.50 for five consecutive trading days and trading volume in that period is at least US$1,500,000. Management described the financing as flexibility to support expansion across Singapore, Malaysia and China.
EUDA (NASDAQ: EUDA) announced on October 23, 2025 that its wholly owned subsidiary CK Health Plus will expand into India via a master license and representative partnership with SafeRock India.
The agreement aims to deploy CK Health Plus’ Bioenergy Capsule Therapies and EUDA Helixé supplements across major Indian cities including Mumbai and Bangalore, leveraging SafeRock India’s systems integration capabilities and nationwide network to roll out a network-marketing wellness ecosystem.
EUDA Health Holdings (NASDAQ: EUDA) announced on October 20, 2025 that its wholly owned subsidiary CK Health Plus received a Malaysian Direct Selling License (AJL 932509) from the Ministry of Domestic Trade and Cost of Living.
The License authorizes nationwide direct selling and multi-level marketing activities, including member recruitment, distribution of EUDA Helixé supplements, and operation of Bioenergy Capsule Centers. CK Health Plus said it will roll out centers and expand its agent network across Malaysia and strengthen synergies with Singapore operations while providing product training to agents to ensure ethical wellness education.
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has signed a Letter of Intent to potentially acquire GO POSB Organoids, a Singapore biotechnology company. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that converts human blood cells into clinical-grade stem cells.
The companies plan to establish an iPSC laboratory and cultivation facility in Shenzhen, China, collaborating with Singapore's A*STAR for research and clinical trials. The facility aims to serve as a distribution hub for iPSC solutions across China, pending regulatory approvals. The initiative aligns with EUDA's strategy to expand its stem cell treatments and supplements portfolio.
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has secured distribution rights for T-cell immunotherapies in Malaysia through a partnership with Shenzhen Inno Immune Co. Ltd. This marks EUDA's second major cell therapy initiative following its April 2025 stem cell therapy distribution partnership.
The agreement, facilitated through Guangdong Key Lock Health Management Co., allows EUDA's subsidiary CK Health Plus Sdn Bhd to market and sell T-cell immunotherapies in Malaysia at USD 8,000 per treatment, significantly lower than regional market prices. Shenzhen Inno brings strong credentials including a GMP-standard cell preparation center, Peacock Plan recognition, and Sequoia Capital backing.
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has signed a Letter of Intent (LOI) to potentially acquire Chemokine Pte Ltd, a Singapore-based biotech company. The LOI includes a 120-day exclusivity period during which Chemokine cannot engage in discussions with other potential buyers.
Chemokine, founded by Professor Kah Meng Lim, specializes in molecular supplements and gene modulating formulations. The company has previously granted EUDA exclusive worldwide distribution rights to its next-generation immune health supplement, which EUDA will market as Euda Helixé. The supplement combines molecular deer placenta, marine collagen, and bioactive antioxidants, utilizing a gene activation model designed to modulate gene expression.